Fabentech’s diverse portfolio features life-saving solutions designed to neutralise the most critical viruses and biological toxins, providing a crucial defence against potentially deadly threats.

Indication Proof of concept Preclinical stage Clinical stage Development completed


The resurgence of bioterrorism plots involving the use of biological toxins highlights the importance of protecting ourselves against potential attacks. In this context, we are building a therapeutic arsenal of specific and effective medical countermeasures.

Biodefence antidote #1

Clinical stage

Fabentech has initiated, in collaboration with Ministry of Defence and the DGA [General Directorate of Armaments], a partnership aiming to develop, produce and market an antidote to combat a plant-based toxin categorised as a top-priority biothreat with neither vaccines nor treatments available at this stage.

Read more

Biodefence antidote #2

Proof of concept

Fabentech is leading a proof-of-concept study targeting a new identified plant-based toxin. This program is supported by the European Defence Fund through the European COUNTERACT project, coordinated by CEA. It is aiming to increase EU preparedness for immediate response to Chemical-Biological Radiological and Nuclear (CBRN) threats.

Read more

Biodefence antidote #3

Proof of concept

Fabentech has initiated a project aimed at developing a treatment for a new plant toxin, identified as a priority for public health.

Read more

Emerging infectious diseases

Fabentech has over 14 years of expertise in the Research and Development of immunotherapies against emerging infectious diseases.

Since 2009, Fabentech has been involved in programmes intended to combat H5N1 avian influenza, the Ebola haemorrhagic fever and the Crimean-Congo hemorrhagic fever (CCHF). Fabentech has notably developed a product against the H5N1 avian influenza (FabenFLU®) and a product against Ebola under the aegis of the World Health Organisation (WHO) and with the support of the European Medicines Agency (EMA).

EID treatment #1 FabenFLU®

Development completed

Treating post-exposure H5N1 avian influenza infection

H5N1 avian influenza causes a highly infectious, severe respiratory disease in humans, with a mortality rate reaching 60%¹. The virus primarily spreads from birds to humans with few cases of human-to-human transmission. There are currently no treatments available. If the virus were to mutate and become easily transmissible among humans, it could lead to a global pandemic.

FabenFLU® is fully validated anti-H5N1 antidote and obtained an Orphan Drug Designation status in the EU.

Read more

EID treatment #2 FabenCOV®

Clinical study

Treatment against Sars-Cov-2 infections

Covid-19 infection is a respiratory illness caused by the SARS-CoV-2 virus, which can lead to a range of symptoms from mild to severe, and has resulted in a global pandemic². FabenCOV® treatment is designed to treat infected adults at risk with comorbidities.

This project has received funding from both BPI France and the European Union’s Horizon Europe research and innovation programme.

To discover more about this project, visit epic-crown-2.com

Read more

EID treatment #3 NIPAH

Proof of concept

Treatment against Nipah infections

Nipah virus is an infectious agent causing a severe respiratory and neurological disease with fatality rate ranging from 40 to 75% with neither vaccines nor treatments available³. Nipah infection is a zoonotic viral disease with evidence of human-to-human transmissions primarily through close contact and possibly through airborne transmission.

This project aims to develop treatment of post-exposure Nipah infection and is funded through France 2030 Emerging Infectious Diseases programme.

Read more


Proof of concept

Treatment against infections caused by viruses from the Sarbecovirus family

Sarbecoviruses are viruses responsible for severe respiratory diseases in humans and exhibit a high mortality rate and strong mutation capacity.

The developed product aims to produce an innovative broad-spectrum antiviral therapy to combat several viruses from the Sarbecovirus family. It will also be capable of neutralizing mutations emerging within this family. The development of this treatment is funded by the European Commission, as part of the e-FabRIC Consortium.

To discover more about this project, visit efabric.org

Read more


¹ WHO – Influenza H5N1 – Influenza: H5N1 (who.int)

² WHO – Coronavirus Disease (Covid-19) – Coronavirus (who.int)

³ WHO – Nipah Virus – Nipah virus (who.int)